Bordetella Pertussis, Whooping Cough
7
1
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (7)
CARE-ID: Dynamics of Respiratory Infections in Children and Transmission in Households and Schools
Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children
Pertussis Challenge Study in Adults Vaccinated With BPZE1
Impact of Bacterial Expression and Immune Response in the Severity of Pertussis
Pertussis Immunization Programs in Low Income Countries
Pertussis Immunization Programs in Low Income Countries - Ivory Coast
EUpertstrain 4 Study of Bordetella Pertussis Isolates